Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS, United States.
Curr Opin Pharmacol. 2019 Aug;47:14-19. doi: 10.1016/j.coph.2019.01.006. Epub 2019 Feb 15.
Peptides are a promising new therapeutic approach for glioblastoma with potential for more effective targeting and fewer devastating side effects compared to conventional cancer therapies. With the specificity to target receptors which are uniquely or overexpressed on cancer cells as well as accurately targeting dysregulated signaling pathways, peptides demonstrate a high potential for the treatment of even the most aggressive cancers. By binding to these targets, peptides can be used to deliver drugs, serve as antagonists to various ligands, or, given some inherent anticancer activity, provide additional treatment options alone or in combination therapy. The highly specific targeting capacity of peptides is critical to achieve effective cancer treatment with limited side effects, and in preclinical studies peptides have shown to have both cell and blood brain barrier penetrating capacity. As tumor targeting peptides move beyond the preclinical setting, identification of additional glioblastoma-specific peptide ligands becomes imperative to expand the potential of this encouraging treatment strategy.
肽是胶质母细胞瘤有前途的新治疗方法，与传统癌症治疗相比，具有更有效的靶向性和更少的破坏性副作用。肽具有针对在癌细胞上独特或过表达的受体的特异性，以及针对失调的信号通路的精确靶向性，显示出治疗即使是最具侵袭性癌症的高潜力。通过与这些靶点结合，肽可用于递送药物，作为各种配体的拮抗剂，或者，由于具有一些固有抗癌活性，单独或联合治疗提供额外的治疗选择。肽的高度特异性靶向能力对于实现有效治疗癌症和限制副作用至关重要，并且在临床前研究中，肽已显示出具有细胞和血脑屏障穿透能力。随着肿瘤靶向肽超越临床前环境，识别额外的胶质母细胞瘤特异性肽配体变得至关重要，以扩大这一令人鼓舞的治疗策略的潜力。
